Raúl oversees and coordinates the identification and evaluation of investment opportunities from both scientific and business perspectives at Ysios Capital.
Prior to joining Ysios in 2008, Raúl first worked in corporate business development (Licensing In and Licensing Out) at Laboratorios Almirall. He was subsequently responsible for developing and managing the business of the Company in the Americas and Africa through licensees and distributors.
Raúl was initially trained as a researcher in central nervous system pharmacology within the Department of Pharmacology of the University of the Basque Country (UPV-EHU), and in neurochemistry within the Department of Neurochemistry at the Institute for Biomedical Research of the Barcelona–Spanish National Research Council (IIBB-CSIC).
Raúl holds a Bachelor’s degree in Biological Sciences from UPV-EHU, and a PhD in Neuroscience from UPV-EHU and the CSIC.
Raúl is Chairman of Anaconda Biomed and Board member at Synendos, CorWave. Formerly he was Board member at STAT-Dx (acquired by Qiagen), Prexton Therapeutics (acquired by Lundbeck) and MedLumics.